Elekta (OTCMKTS:EKTAY) Sees Large Volume Increase – Should You Buy?

Elekta AB (OTCMKTS:EKTAY) shares saw unusually-high trading volume on Thursday. 7,211 shares traded hands during mid-day trading, an increase of 160% from the average daily volume of 2,778 shares. The stock last traded at $6.16 and had previously closed at $6.00.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded shares of Elekta from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 28th. One equities research analyst has rated the stock with a Hold rating. According to MarketBeat.com, the company currently has an average rating of “Hold”.

Elekta Stock Performance

The stock has a 50 day moving average of $5.45 and a 200 day moving average of $5.69. The company has a quick ratio of 0.62, a current ratio of 0.86 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $2.27 billion, a price-to-earnings ratio of -51.33 and a beta of 1.01.

Elekta (OTCMKTS:EKTAY) last announced its earnings results on Thursday, August 27th. The company reported $0.07 EPS for the quarter. Elekta had a positive return on equity of 13.47% and a negative net margin of 2.38%. The business had revenue of $372.30 million for the quarter. As a group, analysts predict that Elekta AB will post 0.43 EPS for the current year.

Elekta Company Profile

Elekta AB is a Sweden-based medical technology company that develops and supplies systems and software for radiation therapy, radiosurgery and related cancer-care applications. Its solutions are designed to help hospitals and clinics treat tumors while supporting more precise, personalized and less invasive care.

The company’s portfolio includes linear accelerators, stereotactic radiosurgery systems, magnetic resonance-guided radiation therapy technology and brachytherapy products. Elekta also provides oncology information systems and workflow software, including platforms used for treatment planning, patient management and clinical data coordination.

Founded in 1972 by neurosurgeon and inventor Lars Leksell, Elekta initially focused on radiosurgery and later expanded into broader radiation oncology.